Posted by Michael Wonder on 17 Jan 2023
Stada and Xbrane receive approval for Ximluci
17 January 2023 - Stada and Xbrane have announced that the UK’s MHRA has provided a marketing authorisation for Ximluci.
Also known as ranibizumab, the therapy is a biosimilar which references Lucentis.
The specific British marketing authorisation was granted via the European Commission (EC) Decision Reliance Procedure, during which the MHRA relied on the decision taken by the EC in November last year to issue a centralised marketing authorisation for the treatment’s usage across 27 EU member states, as well as in Iceland, Norway and Liechtenstein.
